A multi-center, placebo-controlled, double blind multiple-ascending dose study in a leapfrog design to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease.

Trial Profile

A multi-center, placebo-controlled, double blind multiple-ascending dose study in a leapfrog design to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs RG 7103 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 26 Oct 2016 Status changed from completed to withdrawn prior to enrolment.
    • 25 Mar 2010 Status changed from recruiting to completed as reported by Roche record.
    • 18 Feb 2010 Planned number of patients changed from 30 to 35 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top